| Drug Name: | Enoxaparin (9005-49-6) |
|---|---|
| PubChem ID: | 772 |
| SMILES: | CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O |
| InchiKey: | HTTJABKRGRZYRN-UHFFFAOYSA-N |
| Therapeutic Category: | Anticoagulants, Cardiovascular Agents, Fibrin Modulating Agents, Fibrinolytic Agents, Hematologic Agents |
| Molecular Weight (dalton) | : | 1134.93 |
| LogP | : | -10.7119 |
| Ring Count | : | 0 |
| Hydrogen Bond Acceptor Count | : | 30 |
| Hydrogen Bond Donor Count | : | 15 |
| Total Polar Surface Area | : | 610.49 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Abciximab (143653-53-6) | Bleeding | Additive | Not clear | Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS |
| dihydroergotamine (6190-39-2) | Ergotism | Synergistic | heparin results in a 25% increase in the AUC of subcutaneously administered dihydroergotamine | Ergotism as complication of thromboembolic prophylaxis with heparin and dihydroergotamine |
| dihydroergotamine (6190-39-2) | Peripheral Ischaemia | Synergistic | heparin results in a 25% increase in the AUC of subcutaneously administered dihydroergotamine | Ergotism as complication of thromboembolic prophylaxis with heparin and dihydroergotamine |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category